TNF-alpha Receptor as Marker for Psoriasis

Title: Soluble tumor-necrosis-factor-alpha receptor type-1 as a marker of activity of psoriasis vulgaris and effects of its treatment
: Serwin AB, et al.
Publication: Przegl Lek. 2005;62(2):95-7.

The authors wanted to examine the serum or blood concentration of soluble tumor necrosis factor alpha type I (sTNF-R1) in patients with psoriasis, and compare this to the severity of the lesions and effectiveness of treatment.

In order to do this, the authors enrolled 34 patients and measured the severity of the psoriatic lesions and serum concentration of STNF-R1 before and after 2 weeks of treatment. They also enrolled 30 healthy volunteers as control. The severity of psoriatic lesion was quantified using PASI (Psoriasis Area and Severity Index).

The authors found that:

Before Treatment
After Treatment
12.98 +/- 5.77
6.17 +/- 2.12
1.88 +/- 0.41 ng/ml
1.65 +/- 0.46 ng/ml

The authors found that the concentration of sTNF-R1 was significantly lower in the healthy control subjects (1.48 +/- 0.3 ng/ml) as compared to pre-treatment level in the psoriasis patient.

The authors concluded that there was a significant correlation between the level of serum tumor necrosis alpha type I with the severity of psoriasis, and that this level decreased after treatment. They suggested that sTNF-R1 level could serve as a marker of activity of psoriasis vulgaris.

Main Menu
Health Articles
Health News
Health Research
Site Map

Health Conditions
Cardiovascular Health
Digestive Health
Infectous Diseases
Musculoskeletal Health
Pregnancy & Childbirth
Skin Health

Misc. Health Articles
Presidential Diseases

Medical Research

Psoriasis Overview
Psoriasis Pictures
Research Summaries

©copyright 2004 - Health In Plain English. All Rights Reserved.

Health Articles Health News Health Research Explained in Plain English